Drug Type Bispecific antibody |
Synonyms GBD 201, GBD-201, GBD201 |
Target |
Action inhibitors |
Mechanism CCR8 inhibitor(C-C chemokine receptor type 8 inhibitor), CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | China | 02 Nov 2023 | |
Non-Small Cell Lung Cancer | Preclinical | China | 15 Nov 2021 |